Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | MMP8 | P22894 | 4/20 | 0.49 |
| ▸ | MMP13 | P45452 | 4/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13537866 | 0.91 | MMP1 (0.51) | SPPL2AMMP1MMP2MMP9MMP8 | |
| SCHEMBL13537897 | 0.91 | SPPL2A (0.56) | SPPL2AMMP2MMP13 | |
| SCHEMBL13631029 | 0.91 | SPPL2A (0.56) | SPPL2AMMP2MMP13 | |
| SCHEMBL13617756 | 0.88 | SPPL2A (0.48) | SPPL2AMMP1MMP2MMP9MMP8 | |
| SCHEMBL13537896 | 0.86 | SPPL2A (0.51) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL12103338 | 0.85 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL13569346 | 0.85 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL1104908 | 0.85 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2218623 | 0.85 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2961490 | 0.85 | SPPL2A (0.57) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | SPPL2A 1140/4885MMP1 1106/4885MMP2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.